Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 250Carcinoma, Renal Cell 89Urinary Bladder Neoplasms 67Breast Neoplasms 41Carcinoma, Transitional Cell 37Colorectal Neoplasms 33Ovarian Neoplasms 32Melanoma 31Carcinoma, Non-Small-Cell Lung 31Kidney Neoplasms 30Neoplasms 28Neoplasm Metastasis 26Sarcoma 25Uterine Cervical Neoplasms 20Lung Neoplasms 20Endometrial Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Wilms Tumor 17Adenocarcinoma 17Stomach Neoplasms 16Pancreatic Neoplasms 16Carcinoma, Hepatocellular 16Triple Negative Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Metastatic Castration-resistant Prostate Cancer 13Esophageal Neoplasms 13Rhabdomyosarcoma 12Osteosarcoma 12Neuroblastoma 12Head and Neck Neoplasms 12

Interventions

darolutamide 2Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × Genitourinary × 30 days × Clear all
NCT07395804 2026-05-29

23146

Bayer

Recruiting
500 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06661122 2026-05-19

HAYATE

Bayer

Recruiting
100 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡